Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/26/2025

Management of Hypertensive Emergencies

First-Line Therapy

  • The European Society of Cardiology guidelines recommend labetalol as first-line therapy for most hypertensive emergencies, including malignant hypertension, hypertensive encephalopathy, acute ischemic and hemorrhagic stroke, and severe pre-eclampsia/eclampsia, due to its combined alpha-1 and beta-adrenergic blockade, providing smooth blood pressure reduction without reflex tachycardia 1, 2, 4
  • Labetalol is preferred for malignant hypertension, with a recommended MAP reduction of 20-25% 1

Alternative Agents for Bradycardia

  • The European Society of Cardiology guidelines suggest using nicardipine or clevidipine as first-line agents for severe hypertension with bradycardia, as they provide effective blood pressure reduction without negative chronotropic effects 1, 2, 4
  • Nicardipine can be started at a dose of 5 mg/h IV, titrated by 2.5 mg/h every 5 minutes to a maximum of 15 mg/h, although this specific dosing guideline is from Praxis Medical Insights, the use of nicardipine is supported by European Heart Journal 1, 2, 4
  • Other bradycardia-safe alternatives include hydralazine for severe pre-eclampsia, nitroprusside for acute pulmonary edema or aortic dissection, and nitroglycerin for acute coronary syndromes with hypertension 1, 4, 5

Special Considerations

  • In the case of acute aortic dissection, esmolol (an ultra-short acting beta-blocker) combined with nitroprusside is recommended to achieve both heart rate reduction to <60 bpm and blood pressure reduction to <120 mmHg systolic, due to its ability to rapidly titrate and reverse if excessive bradycardia develops 4